Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsCareSource Dual Advantage Formulary Coverage & PA …
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentCareSourcePolicy N/A

    CareSource Dual Advantage Formulary (Drug List) — Coverage Criteria

    Customize your policy alerts

    Sign up for all CareSource policy alerts

    Know when CareSource releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Describes the prescription drugs covered by the CareSource Dual Advantage (HMO D-SNP) plan, how to use the formulary, and coverage controls (prior authorization, quantity limits, step therapy) for members and prescribing providers.

    Policy Summary
    PayerCareSource
    PolicyCareSource Dual Advantage Formulary (Drug List) — Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateApr 1, 2026
    Last ReviewApr 1, 2026
    Next Review DateN/A
    Key ActionObtain required prior authorization (PA) before dispensing or administering drugs flagged with PA to avoid claim denial.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    04/01/2026formulary effective/updated date
    00026138formulary identifier
    multiplePA entries
    severalQL entries
    30dTemporary supply

    Coverage rules and formulary controls

    Formulary Coverage and Controls

    Covered when plan rules and site/network requirements are met.

    General formulary coverage: Drug is generally covered if it is listed on the formulary, is medically necessary, dispensed at a CareSource Dual Advantage network pharmacy, and other plan rules are followed.

    See Evidence of Coverage for details.

    Coverage controls: Coverage may be subject to utilization management controls such as prior authorization, quantity limits, and step therapy as indicated for specific drugs.

    See formulary Requirements /Limits codes for per‑drug controls (PA, QL, ST, MO, LA, NDS, B/D PA).

    Formulary Exception Criteria

    Formulary exceptions and coverage waivers are considered under the following logic.

    Policy Summary
    PayerCareSource
    PolicyCareSource Dual Advantage Formulary (Drug List) — Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateApr 1, 2026
    Last ReviewApr 1, 2026
    Next Review DateN/A
    Key ActionObtain required prior authorization (PA) before dispensing or administering drugs flagged with PA to avoid claim denial.
    SourceLink
    On This Page
    Coverage rules and formulary controlsFormulary coding, NDCs, and dosage annotationsPrior authorization, step therapy, documentation, and denial risksStep therapy and related program controlsQuantity limits by drug and formulationSite-of-care and administration restrictionsAbbreviations and glossaryContext and biosimilar policy notesPolicy revision and effective dates
    Formulary exception approval conditions:
    An exception to the formulary or a waiver of a restriction (PA, ST, or QL) will generally be approved when the prescriber documents that formulary alternatives would not be as effective for the member or would cause adverse effects, or that applying the restriction would not be as effective for the member.

    Prescriber must submit supporting medical rationale; standard decision timeframe is 72 hours and expedited (urgent) requests with a prescriber statement are decided within 24 hours.

    Exception procedures: Member or prescriber must request an exception and provide the required clinical justification; CareSource will make a decision within the stated timelines.72 hours (standard); 24 hours (expedited)

    If approved, coverage and cost‑sharing are applied per the decision (e.g., non‑formulary approvals remain at pre‑determined cost‑sharing).

    Temporary Supply / Transitional Coverage

    Temporary supply coverage rules.

    Initial temporary supply: Plan will cover a temporary 30‑day supply for each non‑formulary or restricted drug during initial coverage while the member pursues an exception or waiver.30 days

    If coverage is not approved after the initial 30‑day supply, the plan will not pay for subsequent fills.

    Emergency or transitional supply: For long‑term care residents or certain transitions in care, the plan may provide a one‑time emergency/temporary supply up to 31 days while the member pursues a formulary exception.31 days

    Applies to LTC residents past the first 90 days of membership or to specified transitions of care (hospital discharge, hospice change, facility discharge, etc.).

    One‑time site‑of‑care transition supply: If the treatment setting changes (e.g., hospital discharge to home, transition from Part A facility coverage to Part D), the plan may cover a one‑time temporary supply up to 31 days.31 days

    Applies to the specified transition events listed in policy.

    General coverage rules for listed agents

    Coverage is determined per listed drug/formulation when ALL of the following apply:

    Formulary presence: The specific drug and formulation is listed in the in‑network prescription drug benefits table for the plan.

    Listing indicates coverage is subject to the Requirements /Limits field for that line item.

    Utilization controls complied: The provider and member comply with any utilization management controls shown on the drug line (for example, obtain Prior Authorization (PA), meet Step Therapy (ST) requirements, or adhere to Quantity Limits (QL)).

    Requirements /Limits codes (PA, MO, QL, NDS, LA, B/D PA, ST) on each drug line must be satisfied for coverage.

    Network and site requirements met: Dispensing occurs through an in‑network pharmacy or the appropriate site of care as required (LA, B/D PA may indicate site or Part B/Part D billing distinctions).

    Some agents (IV/infusible/specialty) may require administration in specified settings and follow site‑of‑care rules.

    Non‑maintenance formulary changes generally will not discontinue or reduce coverage of drugs during the 2026 coverage year for members already taking them. Members who are currently using a drug that remains on their plan will continue to receive it at the same cost‑sharing and with no new restrictions for the remainder of the 2026 coverage year; changes that do not affect the member will not generate a direct notice. Note that formulary changes may take effect for all members on the next benefit year (for example, January 1 of the following year).

    Source material: CareSource statement on formulary changes and the 2026 coverage year.

    If a drug is not included on the formulary and an exception is not granted, the member may be responsible for the full cost of the medication. Members should contact Member Services to confirm coverage and request a list of covered alternatives to discuss with their prescriber, or submit a formulary exception request with supporting medical rationale so the plan can consider covering the non‑formulary drug.

    There are no explicit plan exclusions stated within this segment of the formulary extract. The fragment lists covered agents and applicable Requirements/Limits flags but does not present any standalone exclusion statements in these chunks.

    This excerpt does not contain specific exclusion language; instead, the drug table uses abbreviated Requirement/Limits codes (for example, PA, MO, QL, NDS, LA, B/D) whose full definitions and any exclusionary rules are provided at the start of the complete formulary table. Refer to the table header/legend in the full formulary for the authoritative meanings of those abbreviations.

    No entries in this segment explicitly list conditions or situations described as 'not medically necessary.' The fragment shows drugs with usage flags (PA, MO, QL, NDS) but does not enumerate 'not medically necessary' determinations in these chunks.

    Formulary coding, NDCs, and dosage annotations

    No explicit billing codes in this segmentmixed
    No codes listed
    Formulations and strengths notedmixed
    300 mg/15 mlirinotecan intravenous solution (concentration/supply)
    500 mg/25 mlirinotecan intravenous solution (concentration/supply)
    40 mg/2 mlirinotecan intravenous solution (concentration/supply)
    3 mgITOVEBI ORAL TABLET 3 MG
    9 mgITOVEBI ORAL TABLET 9 MG
    100 mgimatinib oral tablet 100 mg
    400 mgimatinib oral tablet 400 mg
    Dosage/supply annotationsmixed
    10 mg/dayLENVIMA ORAL CAPSULE dosing pattern listed
    12 mg/dayLENVIMA dosing pattern
    14 mg/daycapsule dosing patterns (multiple drugs)
    100 mcg/ml; 500 mcg/ml; 1000 mcg/mloctreotide acetate injection solution concentrations
    NDC group notedNDC
    NDCS starting with 61314PYZCHIVA (only NDCs starting with 61314) intravenous and subcutaneous presentations
    Example quantity limit — atorvastatin 40 mg
    Drugatorvastatin 40 mg
    Quantity limit1 tablet per day per prescription
    Source noteListed as example QL in formulary restrictions section
    Quantity limits examples — posaconazole
    Drugposaconazole oral tablet, delayed
    Quantity limitQL (96 per 30 days) depending on entry
    Alternate designationMay be listed NDS (limited to 30-day supply) for some rows
    Quantity limits examples — multiple entries
    Example 1MAVYRET ORAL TABLET — QL (84 per 28 days)
    Example 2PAXLOVID ORAL TABLETS, DOSE PACK 300 MG — QL (30 per 30 days) or QL (28 per 28 days) depending on row
    Example 3cefuroxime sodium IV recon soln 7.5 g — QL (20 per 10 days)
    Quantity limits examples — selected QL patterns
    Example QL setExamples include QL (20 per 10 days); QL (224 per 28 days); QL (4 per 10 days); QL (80 per 10 days)
    ContextThese appear on IV/anti‑infective lines and other formulary rows with NDS/PA flags
    ImplicationDispensing must not exceed stated time‑period limits unless override documented
    Quantity limits examples — common QL patterns
    Representative QLsExamples include QL (324 per 30 days); QL (90 per 30 days); QL (28 per 28 days); QL (120 per 30 days)
    Where shownAppears across oncology and specialty oral/IV product listings
    LegendQL values shown alongside PA/MO/NDS in Requirements/Limits column

    Prior authorization, step therapy, documentation, and denial risks

    Prior Authorization

    Prior authorization required

    Prior Authorization Required: CareSource requires prior authorization (PA) for many drugs and drug formulations listed in the formulary. Providers or prescribers must obtain approval from CareSource before dispensing PA‑flagged products; claims for items requiring PA may be denied if authorization is not obtained.

    • PA = Prior Authorization — approval required before fill; absence of PA may result in non‑coverage or claim denial.
    • PA appears widely in the Requirements/Limits column across formulary (including oncology, specialty, biologic, infusion, IV, and oral agents).
    Prior Authorization

    PAXLOVID prior auth / quantity limits

    PAXLOVID: Specific prior authorization and quantity limits apply. Some PAXLOVID dose packs are listed with site/medical override (MO), NDS flags, and explicit QL entries (for example QL 28/28 days or QL 30/30 days depending on pack). Providers must follow the listed Requirements/Limits for the exact package/NDC.

    • PAXLOVID dose packs: some entries show MO; NDS; others show PA; MO; QL (28 per 28 days) or QL (30 per 30 days).
    • Dispense only per the QL shown for the specific pack size to avoid denial.
    Prior Authorization

    Prior authorization required for select agents

    Prior authorization is required for select agents (including many specialty, infusion, oncology, and biologic products). Prescribers must request PA before dispensing these agents to ensure coverage.

    • Examples of select agents with PA flags: intravenous antibiotics, antiviral IV/PO formulations, selected oncology and specialty agents.
    • Some entries additionally show B/D PA (benefit/design PA) or site flags — follow the exact Requirements/Limits for each product.
    Prior Authorization

    Prior authorization required for many drugs

    Prior authorization is required for many drugs across the formulary; PA is used alongside other controls (MO, QL, LA, ST, NDS, B/D PA) to manage utilization. Verify Requirements/Limits for each product before dispensing.

    • PA often appears with MO (medical override), QL (quantity limits), LA (limit by administration site), ST (step therapy), and NDS (non‑drug specific notes).
    • B/D PA denotes benefit/design prior authorization pathways for certain products (e.g., some oncology agents, biologics).
    Documentation Required

    Prior authorization requirements

    Prior authorization requirements: when PA is indicated in the Requirements/Limits column, prescribers must submit the supporting clinical documentation requested by CareSource. Follow the table legend for symbol definitions and exact procedural expectations.

    • Refer to the table header/legend for abbreviation meanings (PA, QL, ST, MO, NDS, LA, B/D PA).
    • PA requests typically require a prescriber statement and clinical rationale; see formulary/web resources for PA forms and instructions.
    Prior Authorization

    Prior authorization required for listed specialty/biologic products

    Numerous listed drugs (including specialty/biologic products such as REPATHA, OTULFI, TREMFYA, PYZCHIVA, TREMFYA, and other high‑cost injectables) are flagged with PA and often QL and MO. These products commonly require prescriber‑submitted documentation prior to coverage.

    • Specialty biologics frequently show PA; many also include QL values (e.g., 0.5 per 28 days, 1 per 28 days, or per‑period limits).
    • B/D PA entries appear for certain biologics and oncology drugs — confirm the correct PA pathway.
    Note

    Authorization indicators present

    Authorization indicators present: the formulary uses abbreviations (PA, MO, QL, ST, LA, NDS, B/D PA) to signal utilization management and approval pathways. Providers must interpret these abbreviations per the table legend and comply before dispensing.

    • PA = Prior Authorization; QL = Quantity Limit; ST = Step Therapy; MO = Medical Override; LA = Limit by Administration site; NDS = Non‑Drug Specific notes; B/D PA = Benefit/Design PA.
    Denial Risk

    Prior authorization risk / Denial triggers

    Denial risk: failure to obtain prior authorization, exceed a quantity limit, or neglect required medical override/step therapy rules may result in claim denial or non‑coverage. Providers should confirm approvals before dispensing to avoid patient or provider liability.

    • Claims for PA‑flagged drugs may be denied if PA is not on file.
    • Exceeding QL values or ignoring MO/ST requirements can also trigger denials.
    Step Therapy

    Utilization management triggers and step therapy notes

    Utilization management triggers used in the formulary include PA, MO, QL, ST, LA, NDS, and B/D PA. These flags determine additional administrative steps required for coverage and may vary by product, formulation, or package size.

    • Use the Requirements/Limits column for each NDC/package to identify the specific triggers and follow the appropriate authorization or documentation process.
    • Step therapy (ST) is present for some products (e.g., select injectables and certain oral agents); where ST is shown, document failure or contraindication of the required step before requesting coverage for later‑line agents.
    Documentation Required

    Quantity limit documentation

    Quantity limits and quantity‑limit documentation: many formulary entries include explicit QL values (for example, 28 per 28 days, 30 per 30 days, 2 per 28 days). Dispensing beyond the stated QL without an approved exception or override risks denial.

    • Follow the QL shown for the specific product packaging/NDC and the time window specified (per 28 days, per 30 days, per 180 days).
    • If additional quantity is clinically necessary, request an exception/waiver with supporting prescriber documentation per the formulary exception process.
    Documentation Required

    Documentation for restrictions and required prescriber support

    Documentation for restrictions and required supporting materials: when PA, MO, ST, QL, LA, NDS, or B/D PA are indicated, providers must submit the prescriber’s clinical statement and any requested supporting records. Exception requests require a prescriber rationale and are generally decided within 72 hours (24 hours for expedited requests when clinically appropriate).

    • When requesting an exception to prior authorization, quantity limits, or step therapy, the prescriber must explain the medical necessity.
    • Expedited review (24 hours) is available when waiting would seriously harm the member; otherwise standard review is within 72 hours.
    Note

    Reference for abbreviations

    Reference for abbreviations / symbol definitions: see the table legend at the beginning of the formulary for full definitions of PA, QL, ST, MO, NDS, LA, B/D PA and other symbols used throughout the Requirements/Limits column.

    • Always consult the table header/legend before interpreting a Requirements/Limits entry.
    • The legend clarifies which flags require prior authorization versus other administrative actions.

    Step therapy and related program controls

    Step therapy ruleDescription
    Must try specified preferred agent(s) before coverage of non-preferred agent is approved
    For some conditions the plan requires trying a specified formulary drug first; the plan will cover an alternative only after failure or intolerance of the required agent (see formulary and Evidence of Coverage).
    Step therapy ruleDescription
    Try formulary-preferred agent first
    CareSource may require that a formulary-preferred drug (Drug A) be tried and fail or be intolerable before covering an alternative (Drug B). See formulary entries for specific ST flags.
    Specialty program examplesControls/flags shown
    CAYSTON
    Listed with Requirements/Limits = PA; MO; LA; QL (84 per 56 days); NDS (managed via specialty/site controls).
    TEFLARO
    Listed with Requirements/Limits = PA; MO; NDS (subject to program controls).
    SIRTURO
    Included among specialty/anti-infective listings with PA/MO and other program flags (see table).
    ObservationSource note
    B/D PA and step-like controls present
    Multiple specialty/oral oncology entries include B/D PA and other flags; explicit step sequences are not provided in this fragment.
    FlagInterpretation
    MO
    Shown across entries; may indicate medical override/site or step management per table header definitions.
    LA
    Limited availability/site-of-care flag appears; may be used as part of step/management controls.
    B/D
    B/D PA appears (brand/dispense prior auth) indicating additional prior step or billing pathway.
    FlagImplication
    B/D PA
    Indicates a brand/dispense prior authorization pathway; may require prior steps or criteria before coverage.
    PA
    Prior authorization flag present across many entries; may signal required prior steps or clinical criteria.
    SummarySource
    Step therapy not explicitly detailed in this excerpt
    Fragment frequently shows MO and PA flags but does not include full step-sequence details or failure criteria.
    Starter/titration referenceExample from formulary
    Starter and titration packs referenced
    Entries include 'STARTING PACK', 'INITIATION PK', and dose packs (e.g., VENCLEXTA STARTING PACK; EXXUA 24HR DOSE PACK) implying staged initiation.
    ProductStep therapy (ST) note
    ARISTADA formulations
    Some ARISTADA intramuscular suspension entries are listed with Requirements/Limits including ST (step therapy) and QL values.
    RuleFormulary indication
    ST applies where listed in Requirements /Limits
    Formulary lines show 'ST' on specific rows (providers must follow the Requirements/Limits field where ST is indicated).
    Products with ST notedFormulary reference
    RALDESY
    Listed with Requirements/Limits = ST; MO; NDS (ST indicated for this product).
    Methylphenidate formulations
    Certain methylphenidate entries include ST in Requirements/Limits (see formulary lines showing ST; MO; QL).
    ObservationImplication
    B/D PA and PA / MO flags indicate benefit-design or step controls
    Some products are flagged B/D PA and MO indicating benefit/benefit-design or step-level controls; explicit multi-step sequences are not present in this excerpt.

    Quantity limits by drug and formulation

    atorvastatin 40 mg — unit
    Drugatorvastatin 40 mg
    Packaged unit1 tablet
    ApplicationExample tablet/day QL used in formulary explanations
    posaconazole entries — QL/NDS
    Drugposaconazole oral tablet, delayed
    Quantity limitQL (96 per 30 days)
    Alternate listingMay be shown as NDS (limited to 30-day supply) in some rows
    Maintenance medications supply limits
    Maintenance supply limitsSome meds limited to 30-day retail/mail supply; extended supplies limited to 90- or 102-day depending on channel
    Legend referenceNDS indicates 30-day limit (see table header)
    Practical noteUse mail-order for long-term maintenance to access extended day supplies
    itraconazole oral capsule — QL 120
    Drugitraconazole oral capsule
    Quantity limit120 per 30 days
    RequirementsListed with MO and QL in formulary
    ganciclovir sodium IV recon soln — QL 168
    Drugganciclovir sodium IV recon soln
    Quantity limit168 per 28 days
    Related entriesAppears with B/D PA and MO flags in antiviral section
    MAVYRET ORAL TABLET — QL 84
    DrugMAVYRET ORAL TABLET
    Quantity limit84 per 28 days
    RequirementsPA; MO; QL; NDS noted
    PAXLOVID ORAL TABLETS, DOSE PACK 300 MG — QL 30
    DrugPAXLOVID ORAL TABLETS, DOSE PACK 300 MG
    Quantity limit30 per 30 days (and some rows show 28 per 28 days)
    RequirementsPA; MO; QL flags across entries
    PREVYMIS ORAL TABLET 240 MG — QL 56
    DrugPREVYMIS ORAL TABLET 240 MG
    Quantity limit56 per 28 days
    Alternate strength480 mg listing shows QL (28 per 28 days)
    cefuroxime sodium IV recon soln 7.5 g — QL 20
    Drugcefuroxime sodium IV recon soln 7.5 g
    Quantity limit20 per 10 days
    NotesListed with NDS and appears in antiinfective section
    cefuroxime sodium IV recon soln 7.5 g — QL 20 (duplicate)
    Drugcefuroxime sodium IV recon soln 7.5 g
    Quantity limit20 per 10 days (duplicate entry)
    SourceSame QL appears across multiple rows in the antiinfective table
    meropenem IV recon soln 500 mg — QL 10
    Drugmeropenem IV recon soln 500 mg
    Quantity limit10 per 10 days
    RequirementsPA; QL indicated in formulary
    vancomycin IV recon soln 5 g — QL 4
    Drugvancomycin IV recon soln 5 g
    Quantity limit4 per 10 days
    NotesListed with QL and MO in IV antibiotic rows
    vancomycin oral capsule 125 mg — QL 40
    Drugvancomycin oral capsule 125 mg
    Quantity limit40 per 10 days
    RequirementsPA; MO; QL flags shown
    abiraterone oral tablet 250 mg — QL 120 or 60
    Drugabiraterone oral tablet 250 mg
    Quantity limitQL (120 per 30 days) or QL (60 per 30 days) depending on listing
    ContextMultiple entries show differing QLs by strength/formulation
    BOSULIF formulations — QL examples
    DrugBOSULIF formulations
    Quantity limit examplesQL examples shown: 30 per 30 days; 56 per 28 days; 112 per 28 days (varies by form)
    RequirementsPA; MO; QL flags noted across entries
    BRUKINSA — QL 84
    DrugBRUKINSA oral tablet
    Quantity limit84 per 28 days
    RequirementsPA; LA; QL indicated
    CALQUENCE — QL 60
    DrugCALQUENCE (acalabrutinib)
    Quantity limit60 per 30 days
    RequirementsPA; LA; QL indicated in formulary
    dasatinib 20 mg — QL 90
    Drugdasatinib 20 mg
    Quantity limit90 per 30 days
    RequirementsPA; MO; QL noted
    erlotinib — QL 120
    Drugerlotinib (various entries)
    Quantity limit120 per 30 days
    RequirementsPA; MO; QL flags across rows
    fulvestrant — QL 126
    Drugfulvestrant
    Quantity limit126 per 28 days
    RequirementsPA; QL indicated
    IBRANCE — QL 120
    DrugIBRANCE (palbociclib)
    Quantity limit120 per 30 days (other entries show 324 per 30 days for some formulations)
    RequirementsPA; QL; NDS flags present
    General large QL examples across drugs
    Representative exampleSome entries across the formulary show large QLs (e.g., 324 per 30 days) depending on drug and formulation
    ImplicationQLs vary widely by drug class and are displayed in Requirements/Limits
    ReferenceSee oncology/specialty sections for per‑entry QLs
    IBTROZI / IDHIFA — QL 90
    DrugsIBTROZI; IDHIFA (examples)
    Quantity limit90 per 30 days (example entries)
    RequirementsPA and QL flags shown
    KADCYLA / mitoxantrone — QL 28
    DrugsKADCYLA; mitoxantrone examples
    Quantity limit28 per 28 days
    ContextTypically shown for IV oncology reconstructions
    irinotecan — QL 21; 42
    Drugirinotecan (various IV solutions)
    Quantity limitsExamples include QL (21 per 28 days) and QL (42 per 28 days)
    NotesValues vary by vial size/strength and row
    NULOJIX — QL 24
    DrugNULOJIX
    Quantity limit24 per 28 days
    RequirementsB/D PA; MO; NDS noted
    OGSIVEO — QL 56
    DrugOGSIVEO
    Quantity limit56 per 28 days
    RequirementsPA; QL specified
    OJEMDA — QL 96
    DrugOJEMDA (various forms)
    Quantity limit96 per 28 days (suspension listing) and other per‑entry QLs
    RequirementsPA; QL; NDS or B/D PA depending on row
    pemetrexed — QL 90
    Drugpemetrexed
    Quantity limit90 per 30 days
    RequirementsPA; MO; LA; QL indicated
    PERJETA — QL 60
    DrugPERJETA
    Quantity limit60 per 30 days
    RequirementsPA; QL indicated
    ROMVIMZA — QL 300
    DrugROMVIMZA
    Quantity limit300 per 30 days
    NotesLarge QL shown for oral solution/pack variants
    Multiple QL examples vary by drug
    SummaryMultiple QL examples vary by drug: 30/30; 60/30; 84/28; 90/30; 120/30; 224/28; 360/30 etc.
    Where seenAcross oncology, neurology, and specialty formulary sections
    ActionConfirm per‑line QL and Requirements/Limits before dispensing
    VALTOCO — QL 10
    DrugVALTOCO (select strengths)
    Quantity limitQL (10 per 30 days)
    RequirementsPA; MO; QL flags present
    SYMPAZAN — QL 60 (alt 30)
    DrugSYMPAZAN oral film
    Quantity limitQL (60 per 30 days); alternate listing QL (30 per 30 days)
    RequirementsPA; MO; QL indicated in formulary
    topiramate — QL 28 per 180 days
    Drugtopiramate formulations
    Quantity limitQL (28 per 180 days)
    NotesApplies to various topiramate forms (capsule/solution/tablet) in this fragment
    BRIUMVI — QL examples
    DrugBRIUMVI
    Quantity limitQL (24 per 180 days); alternate listing QL (12 per 28 days)
    RequirementsPA; MO; QL indicated
    dimethyl fumarate — QL examples
    Productdimethyl fumarate packs (120/240 mg)
    Quantity limitsQL (56 per 28 days); other listings QL (120 per 180 days)
    RequirementsPA; MO; QL flags
    acetaminophen‑codeine solution — QL examples
    Drugacetaminophen‑codeine oral solution
    Quantity limitsExamples include QL (4500 per 30 days), QL (5550 per 30 days), QL (360 per 30 days)
    RequirementsMO; QL flags vary by concentration/packaging
    VUMERITY — QL 120
    DrugVUMERITY
    Quantity limit120 per 30 days
    RequirementsPA; MO; QL indicated
    ZEPOSIA — QL 30
    DrugZEPOSIA
    Quantity limit30 per 30 days
    RequirementsPA; MO; QL indicated
    buprenorphine transdermal patch — QL 4
    Drugbuprenorphine transdermal patch
    Quantity limit4 per 28 days
    RequirementsPA; MO; QL indicated
    fentanyl transdermal patch 72 hr — QL 10
    Drugfentanyl transdermal patch 72 hr
    Quantity limit10 per 30 days
    RequirementsPA; MO; QL indicated in multiple rows
    methadone intensol — QL 90
    Drugmethadone intensol
    Quantity limit90 per 30 days
    RequirementsPA; MO; QL indicated
    ABILIFY ASIMTUFII suspension 960 — QL 3.2
    DrugABILIFY ASIMTUFII suspension 960
    Quantity limit3.2 per 56 days (example) or 2.4 per 28 days in other rows
    RequirementsMO; QL indicated
    ARISTADA IM suspension — example QLs
    ProductARISTADA IM suspension examples
    Quantity limitsExamples include QL (30 per 365 days) or per‑entry QLs (e.g., 3.9 per 56 days; 1.6 per 28 days)
    RequirementsMO; ST; QL flags vary by syringe strength
    INVEGA syringe examples — QL variants
    ProductsINVEGA HAFYERA / TRINZA / SUSTENNA syringes
    Quantity examplesExamples include 0.88 per 90 days; 3.5 per 180 days; 0.75 per 28 days; 0.5 per 28 days depending on strength
    RequirementsMO; QL; NDS flags indicated
    Oral psychotropic agents — common QLs
    CategoryOral psychotropic agents (examples)
    Common QLsMany entries include QL (30 per 30 days; 60 per 30 days; 120 per 30 days)
    RequirementsMO; QL flags vary by formulation/strength
    INVEGA SUSTENNA 78 mg — QL 0.5 per 28 days
    ProductINVEGA SUSTENNA 78 mg syringe
    Quantity limit0.5 per 28 days
    RequirementsMO; QL indicated
    quetiapine — QL 90/60
    Drugquetiapine oral tablet
    Quantity limitsQL 90 per 30 days or QL 60 per 30 days depending on strength/formulation
    RequirementsMO; QL indicated
    risperidone microspheres 12.5 mg/2 ml — QL 2
    Drugrisperidone microspheres IM suspension 12.5 mg/2 ml
    Quantity limit2 per 28 days
    RequirementsMO; QL indicated
    risperidone microspheres 25 mg/2 ml — QL 2
    Drugrisperidone microspheres IM suspension 25 mg/2 ml
    Quantity limit2 per 28 days
    Additional notesAlso includes PA/MO/NDS annotations in some rows
    ZURZUVAE — QL 28 per 365 days
    DrugZURZUVAE oral capsule 20/25 mg
    Quantity limit28 per 365 days
    RequirementsPA; MO; QL flags present
    SODIUM OXYBATE — QL 540
    DrugSODIUM OXYBATE (preferred NDCs)
    Quantity limit540 per 30 days for certain entries
    RequirementsPA; LA; QL flagged in some rows
    enoxaparin 30/60 mg syringes — QL 16.8
    Productenoxaparin subcutaneous syringe 30 mg/0.3 ml, 60 mg/0.6 ml
    Quantity limitQL (16.8 per 28 days)
    RequirementsMO; QL indicated in formulary
    enoxaparin 120/80 mg syringes — QL 22.4
    Productenoxaparin subcutaneous syringe 120 mg/0.8 ml, 80 mg/0.8 ml
    Quantity limitQL (22.4 per 28 days)
    RequirementsMO; QL indicated
    ELIQUIS oral tablet — QL 60
    DrugELIQUIS oral tablet
    Quantity limitQL (60 per 30 days)
    RequirementsMO; QL indicated
    ELIQUIS suspension 0.5 mg — QL 140
    DrugELIQUIS oral tablet for suspension 0.5 mg
    Quantity limitQL (140 per 28 days)
    RequirementsMO; QL indicated
    HEPARIN 5,000 UNIT/ML — QL 775
    ProductHEPARIN injection syringe 5,000 UNIT/ML
    Quantity limitQL (775 per 28 days)
    RequirementsMO; QL indicated
    UPTRAVI — QL 60
    DrugUPTRAVI oral tablet
    Quantity limitQL (60 per 30 days)
    RequirementsPA; MO; LA; QL indicated
    REPATHA — QL 6
    DrugREPATHA
    Quantity limit6 per 28 days
    RequirementsPA; QL indicated
    OTULFI (IV) — QL 104
    ProductOTULFI (IV)
    Quantity limit104 per 180 days
    RequirementsPA; MO; QL indicated
    OTULFI (SC) — QL 0.5
    ProductOTULFI (SC)
    Quantity limit0.5 per 28 days
    RequirementsPA; MO; QL indicated
    PYZCHIVA (IV) — QL 104
    ProductPYZCHIVA (IV)
    Quantity limit104 per 180 days
    NotesNDCs starting with 61314 referenced
    TREMFYA PEN induction — QL 12
    ProductTREMFYA PEN induction
    Quantity limit12 per 180 days (induction pack)
    RequirementsPA; MO; QL indicated
    TREMFYA PEN — QL 6
    ProductTREMFYA PEN maintenance
    Quantity limit6 per 28 days
    RequirementsPA; MO; QL indicated

    Site-of-care and administration restrictions

    Note
    Note
    Note
    Note
    Note
    Note
    Note

    Abbreviations and glossary

    Abbreviation definitions used in formulary
    PAPrior Authorization — approval required before the drug will be covered
    MOMedical Override / Mail-Order designation — review or channel restriction may apply
    QLQuantity Limit — maximum quantity allowed within a specified time period (e.g., '60 per 30 days')
    NDSNDS — indicates limitation to 30-day supply at retail or mail-order (table header definition)
    PA — Prior Authorization definition
    PAPrior Authorization — Plan requires approval from CareSource before coverage; failure to obtain may result in noncoverage
    ContextShown in Requirements/Limits column for many drugs
    Action for providersSubmit prior authorization request with supporting medical documentation per formulary processes
    MO — Medical Override / Mail-Order definition
    MOMO — Mail-Order / Medical Override designation; may indicate channel-specific dispensing or special review
    ImplicationMO entries often reference suitability for mail-order or require medical review
    Provider actionFollow channel instructions (retail vs mail) and supply documentation if MO override requested
    QL — Quantity Limit definition
    QLQuantity Limit — maximum amount covered within specific time period (e.g., '60 per 30 days')
    ExamplesMany formulary lines show QL values (e.g., 30/30, 60/30, 120/30, 28/28)
    ImplicationDispensing beyond QL may require prior authorization or documentation
    NDS — Non-Drug-Specific designation
    NDSNDS — indicates drug is limited to a 30-day supply at retail or mail-order per table header
    UsageOften appears alongside QL/PA to denote supply restriction
    ReferenceSee table header 'List of Abbreviations' for full legend
    PA (table header) — legend reference
    Table header termPA (Prior Authorization) — legend referenced at table start
    PurposeIndicates requirement to obtain plan approval before coverage
    Provider notePA shown per‑line in Requirements/Limits; follow PA submission process
    MO (table header) — legend reference
    MO (table header)MO — Mail-Order / Medical Override as defined in list of abbreviations
    MeaningMay indicate channel or special review requirements
    Provider actionCheck row-specific notes for MO requirements
    QL (table header) — legend reference
    QL (table header)Quantity Limit — specified as amount per time period (e.g., '96 per 30 days')
    Examples in documentMultiple entries across the formulary show QL values
    ImplicationAdhere to per‑line QL or obtain documentation for override
    PA — Requirements/Limits meaning
    PA requirementPrior authorization indicated in Requirements/Limits — approval required before coverage
    ConsequenceWithout PA, the plan may not cover the drug
    Where shownPA appears across many drug rows in the formulary table
    QL — Requirements/Limits meaning
    QL meaningQuantity Limit listed in Requirements/Limits — maximum covered quantity/timeframe
    ExamplesShown as 'QL (96 per 30 days)', 'QL (60 per 30 days)', etc.
    ActionClaims exceeding QL may require supporting documentation or PA
    MO — Requirements/Limits meaning
    MO meaningMO may indicate medical override or mail-order designation and appear in Requirements/Limits
    Operational noteFull definition available at table header; follow per-entry instructions
    Provider actionProvide clinical justification if requesting MO override
    Abbreviations in Requirements /Limits (legend)
    Legend summaryAbbreviations used in Requirements/Limits include PA, MO, QL, LA, NDS (see beginning of table for full definitions)
    ImplicationThese flags indicate utilization controls that must be followed for coverage
    ReferenceConsult formulary table header for exact operational definitions

    Context and biosimilar policy notes

    Background: biological products are inherently more complex than typical small‑molecule drugs and the formulary recognizes biosimilar alternatives. The plan may manage biologicals and their biosimilars through tiering, substitution, or application of utilization controls; interchangeability and substitution rules depend on the product and applicable state law. For specifics on how the plan treats biosimilars and substitution of original biologics, see the formulary’s biosimilar guidance and the Evidence of Coverage.

    Note
    Biosimilar / interchangeability
    BiosimilarBiosimilars: alternatives to original biological products that generally perform similarly and may be substituted depending on state law
    InterchangeabilitySome biosimilars are interchangeable and may be substituted at pharmacy per state law
    Plan actionPlan may add or move biosimilars on formulary; member may request exception to continue originator
    Generic — definition
    DefinitionGeneric drug — FDA-approved drug with same active ingredient as brand-name drug; often substitutable at pharmacy subject to state laws
    Formulary noteCareSource covers both brand-name and generic drugs; generics often cost less
    SubstitutionGenerics usually can be substituted without a new prescription depending on state law

    Policy revision and effective dates

    Formulary effective date: 04/01/2026; this document shows the formulary identifier as Formulary ID: 00026138 and indicates the drug list was last updated on 03/13/2026. The policy header also records a last review on 04/01/2026.

    Additional timing: standard decision timelines for formulary exceptions are noted as 72 hours (standard) and 24 hours (expedited with prescriber statement); temporary supply rules allow a 30‑day transitional supply (and in certain long‑term care or limited access situations a 31‑day emergency supply).